Bowie James Ulrich has made a notable move by acquiring 10,000 stock options in Exozyme Inc., as reported in his recent SEC filing. This acquisition, which took place on October 1, 2026, underscores Ulrich's commitment to the company and may have implications for executive engagement within the biological products industry.
Background
Exozyme Inc. operates in the biological products sector, focusing on innovative solutions in life sciences. The company is incorporated in Nevada and has its fiscal year ending on December 31. Ulrich, who is a director at Exozyme, has a significant stake in the company, holding over 577,000 shares following this transaction. His recent filing, dated October 19, 2026, marks a continued trend of executive involvement in the company's growth.
What the Filing Says
According to the filing, Ulrich's stock option has an exercise price of $6.28 and will vest in twelve quarterly installments starting December 31, 2026. The option is set to expire on October 1, 2033. This acquisition adds to his existing holdings, which now total 577,910 shares.
Impact
This acquisition may affect various stakeholders, including other executives and shareholders at Exozyme. By securing additional options, Ulrich demonstrates a strong belief in the company's potential, which could encourage similar actions from other leaders in the biological products sector.
What's Next
The filing does not say what happens next.